Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Departure of Directors or Certain Officers
15 Apr 24
8-K
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
27 Mar 24
8-K
Other Events
8 Jan 24
8-K
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
9 Nov 23
8-K
Regulation FD Disclosure
6 Nov 23
8-K
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
2 Oct 23
8-K
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 23
8-K
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
11 May 23
8-K
Departure of Directors or Certain Officers
4 Apr 23
Registration and prospectus
S-3
Shelf registration
27 Mar 24
S-8
Registration of securities for employees
27 Mar 24
424B5
Prospectus supplement for primary offering
7 Nov 23
424B5
Prospectus supplement for primary offering
6 Nov 23
S-8
Registration of securities for employees
15 Mar 23
424B5
Prospectus supplement for primary offering
1 Dec 22
424B5
Prospectus supplement for primary offering
30 Nov 22
S-3
Shelf registration
1 Nov 22
S-8
Registration of securities for employees
23 Mar 22
424B4
Prospectus supplement with pricing info
1 Nov 21
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
Other
EFFECT
Notice of effectiveness
8 Apr 24
EFFECT
Notice of effectiveness
8 Nov 22
CORRESP
Correspondence with SEC
3 Nov 22
UPLOAD
Letter from SEC
3 Nov 22
EFFECT
Notice of effectiveness
29 Oct 21
CERT
Certification of approval for exchange listing
28 Oct 21
SEC STAFF
SEC staff action: Order
28 Oct 21
CORRESP
Correspondence with SEC
26 Oct 21
CORRESP
Correspondence with SEC
26 Oct 21
CORRESP
Correspondence with SEC
25 Oct 21
Ownership
4
Conor Kilroy
4 Apr 24
3
Conor Kilroy
4 Apr 24
3
Mark Plavsic
25 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
23 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Janet Jill Hopkins
2 Feb 24
4
Julie B Feder
2 Feb 24
4
los Pinos Elisabet de
2 Feb 24